The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Advancement Program, 2018Role of Neuromelanin in Parkinson's Disease and Brain Aging
Study Rationale:
In Parkinson's disease (PD), there is a selective degeneration of brain cells that contain the dark-brown pigment neuromelanin, especially dopamine-producing cells in part of the... -
Target Advancement Program, 2018Engineering Protective Immune Cells for the Treatment of Parkinson's Disease
Study Rationale:
Toxic proteins produced in the brains of people with Parkinson's disease (PD) are known to set off an immune response. In the course of this response, inflammatory lymphocytes --... -
Improved Biomarkers and Clinical Outcome Measures, 2018Searching for Signs of Parkinson's Disease in the Eye
Study Rationale:
Alpha-synuclein is a protein that clumps in the brains of people with Parkinson's disease (PD). These clumps have also been found in the brain and, recently, the retina -- the back of... -
Target Advancement Program, 2018The Role of Lysosomal Lipid Metabolism in Parkinson's Disease
Study Rationale:
Lysosomes -- tiny bubbles inside the cell responsible for disposing of its waste -- don't work as they should in brain cells of people with Parkinson's disease (PD). Lysosomes are... -
Mitochondrial Biomarkers Program, 2018Mitochondrial DNA Damage in a Pesticide-exposed Cohort
Study Rationale:
Environmental poisons may cause or contribute to some cases of Parkinson’s disease (PD). Mitochondrial impairment is seen in all forms of PD. Some environmental exposures, such as... -
Improved Biomarkers and Clinical Outcome Measures, 2018Cognitive-driven Activities of Daily Living Impairment as a Predictor for Parkinson's Disease Dementia
Study Rationale:
Mild cognitive impairment in Parkinson's disease (PD-MCI) is the highest risk factor for Parkinson's disease dementia (PDD). The core feature for differentiating PDD from PD-MCI is...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.